News
PRTK
2.230
0.00%
0.000
Weekly Report: what happened at PRTK last week (0226-0301)?
Weekly Report · 03/04 09:50
Weekly Report: what happened at PRTK last week (0219-0223)?
Weekly Report · 02/26 09:55
Weekly Report: what happened at PRTK last week (0212-0216)?
Weekly Report · 02/19 09:56
Weekly Report: what happened at PRTK last week (0205-0209)?
Weekly Report · 02/12 09:51
Weekly Report: what happened at PRTK last week (0129-0202)?
Weekly Report · 02/05 09:55
Weekly Report: what happened at PRTK last week (0122-0126)?
Weekly Report · 01/29 09:51
Weekly Report: what happened at PRTK last week (0115-0119)?
Weekly Report · 01/22 09:53
Weekly Report: what happened at PRTK last week (0108-0112)?
Weekly Report · 01/15 09:51
Weekly Report: what happened at PRTK last week (0101-0105)?
Weekly Report · 01/08 09:53
Weekly Report: what happened at PRTK last week (1225-1229)?
Weekly Report · 01/01 09:50
Weekly Report: what happened at PRTK last week (1218-1222)?
Weekly Report · 12/25/2023 09:55
Weekly Report: what happened at PRTK last week (1211-1215)?
Weekly Report · 12/18/2023 09:58
Weekly Report: what happened at PRTK last week (1204-1208)?
Weekly Report · 12/11/2023 09:56
Weekly Report: what happened at PRTK last week (1127-1201)?
Weekly Report · 12/04/2023 09:55
Weekly Report: what happened at PRTK last week (1120-1124)?
Weekly Report · 11/27/2023 09:52
Weekly Report: what happened at PRTK last week (1113-1117)?
Weekly Report · 11/20/2023 09:52
Weekly Report: what happened at PRTK last week (1106-1110)?
Weekly Report · 11/13/2023 09:49
Weekly Report: what happened at PRTK last week (1030-1103)?
Weekly Report · 11/06/2023 09:51
Weekly Report: what happened at PRTK last week (1023-1027)?
Weekly Report · 10/30/2023 09:57
Weekly Report: what happened at PRTK last week (1016-1020)?
Weekly Report · 10/23/2023 09:53
More
Webull provides a variety of real-time PRTK stock news. You can receive the latest news about Paratek Pharmace through multiple platforms. This information may help you make smarter investment decisions.
About PRTK
Paratek Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Its commercial product, NUZYRA (omadacycline), is a once-daily oral and intravenous antibiotic for the treatment of adult patients with community-acquired bacterial pneumonia (CABP), and acute skin and skin structure infections (ABSSSI) caused by susceptible pathogens. Its other commercial product SEYSARA (sarecycline), is a once-daily oral therapy for the treatment of moderate to severe acne vulgaris. The Sarecycline is a narrow spectrum tetracycline designed specifically for dermatological use. It markets omadacycline in the United States as an empiric monotherapy in the indications of ABSSSI and CABP for patients that have both a known or suspected resistant pathogen and at least one significant comorbidity.